AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The FDA's AMDAC unanimously recommends AstraZeneca (AZN)/Sanofi's (SNY) nirsevimab as full immunization against RSV disease for all infants.

FDA Panel Endorses AstraZeneca (AZN), Sanofi's RSV Antibody

AstraZeneca said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that could cure autoimmune diseases.

AstraZeneca signs $2 bln agreement with Quell to develop cell therapies

AstraZeneca PLC (LSE:AZN) is placing an $85 million bet on the autoimmune cell therapy sector with Quell Therapeutics - its latest licensing partner. As well as a promising single treatment 'cure' for Type-1 diabetes, Quell is also working on drugs for inflammatory bowel disease.

AstraZeneca places $85 million bet on autoimmune cell therapy with Quell deal

Sanofi

The U.S. Food and Drug Administration advisers on Thursday backed the use of Sanofi and partner AstraZeneca's experimental antibody to prevent respiratory syncytial virus (RSV) infections in infants.

US FDA panel backs Sanofi-AstraZeneca's preventive RSV therapy

Advisers to the U.S. Food and Drug Administration voted unanimously Thursday to recommend a monoclonal antibody developed by Sanofi SNY, +1.30% and AstraZeneca AZN, +1.28% to protect infants from respiratory syncytial virus. RSV is a common respiratory virus that can cause severe illness in infants and older adults.

FDA advisers vote in favor of AstraZeneca, Sanofi antibody for infant RSV protection

If the Food and Drug Administration approves nirsevimab, it will be the first medical intervention available in the U.S. that can protect infants from RSV.

FDA advisors recommend AstraZeneca antibody to protect babies from RSV

AstraZeneca PLC (LSE:AZN) presented significant new data at a recent global cancer conference, the American Society of Clinical Oncology (ASCO), that further underpins its investment case. That at least is the assessment of Shore Capital in a note that repeated the broker's 'buy' recommendation and £130 price target for shares in the Anglo-Swedish pharma giant.

AstraZeneca: Broker upbeat after American cancer conference data reveal

Options traders are blasting pharma stock AstraZeneca PLC (NASDAQ:AZN) today, after the U.S. Food and Drug Administration (FDA) failed to find any safety issues with the company's experimental respiratory syncytial virus (RSV) therapy for infections in infants.

Options Traders Target Pharma Stock on FDA Buzz

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised no new concerns on Sanofi and partner AstraZeneca's experimental therapy to prevent respiratory syncytial virus (RSV) infections in infants.

US FDA staff flag no new safety issues for Sanofi-AstraZeneca's preventive RSV therapy

AstraZeneca PLC (NASDAQ:AZN ) ASCO Investor Event June 5, 2023 7:00 PM ET CorporateParticipants Andy Barnett - VP Global Head of IR Roy Herbst - Deputy Director, Yale Cancer Center Pascal Soriot - Chief Executive Officer Susan Galbraith - Executive Vice President Oncology R&D Dave Fredrickson - Executive Vice President Oncology Business Sunil Verma - Global Head of Oncology, Medical Leora Horn - Global Clinical Head, Lung Cancer and Lung Cancer Strategy Osama Rahma - Global Clinical Strategy Head, GI Cancer Anas Younes - Senior Vice President, Hematology ConferenceCall Participants Andrew Baum - Citi Viktor Sundberg - Nordia Chris Uhde - SEB Peter Welford - Jefferies Simon Baker - Redburn Tim Anderson - Bernstein Research Emily Field - Barclays Harry Gillis - Berenberg James Gordon - JPMorgan Seamus Fernandez - Guggenheim Andy Barnett A warm welcome everybody to this 2023 ASCO event for investors and analysts and thank you greatly for your continued focus and interest in our company. Just for your information, the presentation is now online, you can access it for those in the room by the QR code on your on your tables.

AstraZeneca PLC (AZN) ASCO Investor Event

At the interim analysis, AstraZeneca's (AZN) drug Andexxa showed superior hemostatic efficacy or in other words improved control of bleeding with targeted anticoagulation reversal versus usual care.

AstraZeneca (AZN) Anticoagulant Drug Study Meets Efficacy Goal

AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed.

AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients

Following FDA's label-expansion approval, AstraZeneca's (AZN)/Merck's (MRK) Lynparza is the first PARP inhibitor approved in combination with a new hormonal agent in mCRPC.

FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer

Intel

Sirius XM Holdings Inc

The growth-focused Nasdaq 100 was hit hard in 2022 and lost a third of its value. Historically, double-digit percentage declines in the major stock indexes represent surefire buying opportunities.

3 Nasdaq 100 Stocks That Are Surefire Buys in June

AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.

AstraZeneca (AZN) Discontinues Brazikumab Development

AstraZeneca said on Thursday that a combination of its cancer drug Lynparza and abiraterone has been approved in the United States for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.

AstraZeneca drug combo gets US nod to treat a type of prostate cancer

British drugmaker AstraZeneca said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

AstraZeneca to stop developing Crohn's disease drug

GREENVILLE, S.C.--(BUSINESS WIRE)--AstraZeneca and Kiyatec, the leader in clinically correlated functional precision oncology, have entered into a multifaceted research agreement to assess therapeutic efficacy of undisclosed preclinical assets using Kiyatec's 3D spheroid screening platform, KIYA-PredictTM. The agreement to utilize Kiyatec's spheroid platform aligns with AstraZeneca's leadership and track record of successfully implementing novel, cutting edge oncology solutions with outside par.

Kiyatec and AstraZeneca Announce a Multifaceted Research Agreement to Generate Novel Preclinical Data Using Kiyatec's 3D Spheroid Screening Platform, KIYA-PredictTM

Alexion Pharma

TEL AVIV, Israel , May 30, 2023 /PRNewswire/ -- BioLight (TASE: BOLT) is proud to report it has signed a research collaboration agreement with Alexion (AstraZeneca Rare Disease), focusing on exploring a groundbreaking technology that utilizes natural tears for the potential diagnosis of retinal diseases. The study, financed by Alexion and BioLight, will evaluate a screening technique (the "Technology") that analyzes components of the tear film, an outer eye surface fluid layer.

BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases

AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the combination of Imfinzi and Lynparza in patients with advanced endometrial cancer.

AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal

Merck

Merck and AstraZeneca both appear to be well-positioned for the future. Both boast above-average dividends that look to remain viable.

Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years

AstraZeneca said on Friday a combination of its cancer drugs Imfinzi and Lynparza when added to platinum-based chemotherapy showed positive results in a late-stage trial in patients with advanced or recurrent endometrial cancer.

AstraZeneca's drug combo shows positive results in late-stage cancer trial

AstraZeneca PLC (LSE:AZN) has hailed the potential of a highly targeted combination of its own drugs with chemotherapy in the battle against endometrial cancer. This followed the read-out from the DUO-E phase III trial, which demonstrated impressive outcomes.

AstraZeneca hails the findings from cancer combination trial

AstraZeneca's price has moved sideways in the past month, after showing good progress for some time. A look at its numbers reveals that it is going strong, and will continue to do so in the foreseeable future. However, it is fairly valued at this time.

AstraZeneca: Think Medium-To-Long Term

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to revolutionize cancer care with new data across its industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 to 6, 2023. More than 130 abstracts will feature 22 approved and potential new medicines across the Company's diverse oncology portfolio and pipeline, including 11 oral presentations and a late-breaking plenary presentation of overall survival (OS) resul.

News for AstraZeneca Stock (AZN)